azd4573
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 24, 2017 (NCT03263637)
Timeline
Indications
Studied for
- Hodgkin Disease · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, T-Cell · Phase 2
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- Cyclin-dependent kinase 9INHIBITOR
CDK9 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05140382 | Phase 2 | Dec 8, 2021 | AstraZeneca |
| NCT04630756 | Phase 1/Phase 2 (Phase 2) | Dec 17, 2020 | AstraZeneca, Parexel |
| NCT03263637 | Phase 1 | Oct 24, 2017 | AstraZeneca |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 2 | 2017 |
| Parexel | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1